Eurostars Granted Project “A Novel Modified Natural Killer (NK) Cell Immunotherapy For The Treatment Of Solid Tumours” –
05 / 17 / 2018
The consortium composed of Glycostem Therapeutics BV (The Netherlands), YUMAB GmbH (Germany), Explicyte (France) and OZ Biosciences SAS (France) will deliver a novel cell-based therapy to treat solid tumours with chimeric antigen receptors (CAR) expressing allogeneic (i.e. from a patient independent donor) natural killer (NK) cells. These CARs strongly improve solid tumour targeting and killing potential. The efficacy of this clinical grade CAR-NK cell product will be validated in a preclinical solid tumour model and the therapy will be ready for clinical studies within 24 months after completion of this project.
The total reward amounts to €3,626,860.00 for the 3-year programme.
“Combining the key expertise of the consortium members will bring innovative insights in the active field of immuno-oncology research. We are looking forward to initiating this strategic project taking advantage of motivating technical challenges to reach attractive therapeutic outcomes” said Alban Bessede, CEO of Explicyte.